Names: Generic: modafinil, Trade name in New Zealand: MODAVIGIL® (MIMS 2015).
Drug class: Central nervous stimulants (Wake- promoting agents) (Ballon and Feifel, 2006)
Formulation: Modavigil ® is formulated as modafinil white to off-white, crystalline powder in tablet form. It is available in tablets containing 100mg of modafinil. Excipients in the tablet are: lactose, strach, pregelatinised maize, maicrocrystaline cellulose, croscarmellose sodium, providone and magnesium stearate (Medsafe, 2015).
Indications: Modavigil ® is indicated as a treatment for excessive daytime sleepiness associated with narcoplasy, obstructive sleep anoea/hypopnoea syndrome in order to improve wakefulness. Due to its wake- promoting effect it can be given to treat …show more content…
Uncommon AE’s include amnesia, arrhythmia cough, diabetes mellitus, dysgeusia, dyskinesia, dysphagia, hypertension/hypotension, migraine, myalgia, peripheral oedema, rhinitis, sweating, thirst, reflux, muscle cramp, urinary frequency, tremor and vomiting. Modafinil can cause complications involving the liver or red blood cell if there is allergic reactions. Some of the unknown side effects include serious skin reaction, e.g., Stevens-Johnson, psychosis, mania, and hallucinations (Dickman, …show more content…
Schizophrenia is condition in which patient have abnormalities in attention, memory, verbal processes, impulsivity and executive function. In first episode psychosis (FEP) deficits are present before a formal diagnosis of schizophrenia can be established. Patient with FEP and schizophrenia share deficits in inhibitory control and verbal memory. The purpose of the study is to probe the mechanisms of action of modafinil across cognitive impairment in first episode psychosis. In psychosis cognitive impairments are important factors of functional outcome, which needs to be treated by antipsychotic medication. Previous studies have shown that modafinil improve attention, memory and executive function in the healthy population and in the patients with Schizophrenia. In this study, forty patient with a first episode of psychosis participated. This involved a placebo controlled, followed by a randomized, double-blind, cross-over styled single oral dose of 200mg modafinil. During the first session, half of the participants randomised to receive a single oral dose of a lactose placebo, followed by 200mg modafinil on the second session and the other half of the participants randomised to receive the modafinil, followed by placebo. Statistical repeated-measures analysis model used to measure executive functioning, memory
Drug class: Central nervous stimulants (Wake- promoting agents) (Ballon and Feifel, 2006)
Formulation: Modavigil ® is formulated as modafinil white to off-white, crystalline powder in tablet form. It is available in tablets containing 100mg of modafinil. Excipients in the tablet are: lactose, strach, pregelatinised maize, maicrocrystaline cellulose, croscarmellose sodium, providone and magnesium stearate (Medsafe, 2015).
Indications: Modavigil ® is indicated as a treatment for excessive daytime sleepiness associated with narcoplasy, obstructive sleep anoea/hypopnoea syndrome in order to improve wakefulness. Due to its wake- promoting effect it can be given to treat …show more content…
Uncommon AE’s include amnesia, arrhythmia cough, diabetes mellitus, dysgeusia, dyskinesia, dysphagia, hypertension/hypotension, migraine, myalgia, peripheral oedema, rhinitis, sweating, thirst, reflux, muscle cramp, urinary frequency, tremor and vomiting. Modafinil can cause complications involving the liver or red blood cell if there is allergic reactions. Some of the unknown side effects include serious skin reaction, e.g., Stevens-Johnson, psychosis, mania, and hallucinations (Dickman, …show more content…
Schizophrenia is condition in which patient have abnormalities in attention, memory, verbal processes, impulsivity and executive function. In first episode psychosis (FEP) deficits are present before a formal diagnosis of schizophrenia can be established. Patient with FEP and schizophrenia share deficits in inhibitory control and verbal memory. The purpose of the study is to probe the mechanisms of action of modafinil across cognitive impairment in first episode psychosis. In psychosis cognitive impairments are important factors of functional outcome, which needs to be treated by antipsychotic medication. Previous studies have shown that modafinil improve attention, memory and executive function in the healthy population and in the patients with Schizophrenia. In this study, forty patient with a first episode of psychosis participated. This involved a placebo controlled, followed by a randomized, double-blind, cross-over styled single oral dose of 200mg modafinil. During the first session, half of the participants randomised to receive a single oral dose of a lactose placebo, followed by 200mg modafinil on the second session and the other half of the participants randomised to receive the modafinil, followed by placebo. Statistical repeated-measures analysis model used to measure executive functioning, memory